A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma
Clinica Chimica Acta · 2024
DOI: 10.1016/j.cca.2023.117634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinica Chimica Acta, 2024. Verfasst von Stéphane Muccio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, TMED-BCB, 371 rue du Professeur Blayac, 34184 Montpellier, France. Electronic address: stephane.muccio@sanofi.com. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
To determine the disease status and the response to treatment for patients with multiple myeloma, measuring serum M-protein levels is a widely used alternative to invasive punctures to count malignant plasma cells in the bone marrow. However, the quantification of this monoclonal antibody, which varies from patient to patient, poses significant analytical challenges. This paper describes a sensitive and specific mass spectrometry assay that addresses two objectives: to overcome the potential interference of biotherapeutics in the measurement of M-proteins, and to determine the depth of response to treatment by assessing minimal residual disease. After immunocapture of immunoglobulins and free light chains in serum, heavy and light chains were dissociated by chemical reduction and separated by liquid chromatography. M-proteins were analyzed by high-resolution mass spectrometry using a method combining a full MS scan for isotyping and identification and a targeted single ion monitoring scan for quantification. This method was able to discriminate M-protein from the therapeutic antibody in all patient samples analyzed and allowed quantification of M-protein with a LLOQ of 2.0 to 3.5 µg/ml in 5 out of 6 patients. This methodology appears to be promising for assessing minimal residual disease with sufficient sensitivity, specificity, and throughput.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sanofi, TMED-BCB, 371 rue du Professeur Blayac, 34184 Montpellier, France. Electronic address: stephane.muccio@sanofi.com.
- Montpellier Univ, IRMB CHU, INM INSERM, 80 avenue Augustin Fliche, 34295 Montpellier, France.
- Sanofi, TMED-BCB, 371 rue du Professeur Blayac, 34184 Montpellier, France.
- Sanofi, TMED-PMO, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France.
Zitieren
APA
Muccio, S., Hirtz, C., Descloux, S., Fedeli, O., Macé, S., Lehmann, S., & Vialaret, J. (2024). A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2023.117634
Vancouver
Muccio S, Hirtz C, Descloux S, Fedeli O, Macé S, Lehmann S, et al. A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma. Clinica Chimica Acta. 2024. doi:10.1016/j.cca.2023.117634
BibTeX
@article{Muccio2024,
author = {Muccio, Stéphane and Hirtz, Christophe and Descloux, Sandrine and Fedeli, Olivier and Macé, Sandrine and Lehmann, Sylvain and Vialaret, Jérôme},
title = {A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma},
journal = {Clinica Chimica Acta},
year = {2024},
doi = {10.1016/j.cca.2023.117634}
}
EUVIMED